Lyell Immunopharma, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Lyell Immunopharma, Inc. (LYEL) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $126.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $126.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $97.90M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $47.80M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $126.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $97.90M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | $47.80M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $92.30M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $82.80M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $31.70M 10-K · filed 2026-03-12 |
| 2024-09-30 | $22.30M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $338.20M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $358.60M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $117.80M 10-K · filed 2025-03-11 |
| 2023-09-30 | $247.60M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $261.70M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $230.40M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $287.80M 10-K · filed 2024-02-28 |
| 2022-09-30 | $507.30M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $621.60M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $680.10M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $602.90M 10-K · filed 2023-02-28 |
| 2020-12-31 | $132.60M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |